Difference between revisions of "Part:BBa K1720001:Design"
(→Design Notes) |
(→References) |
||
Line 14: | Line 14: | ||
===References=== | ===References=== | ||
+ | 1. Gheorghiade M, Marti CN, Sabbah HN, Roessig L, Greene SJ, Bohm M, Burnett JC, Campia U, Cleland JG, Collins SP et al: Soluble guanylate cyclase: a potential therapeutic target for heart failure. Heart failure reviews 2013, 18(2):123-134. | ||
+ | |||
+ | 2. Sharina IG, Cote GJ, Martin E, Doursout MF, Murad F: RNA splicing in regulation of nitric oxide receptor soluble guanylyl cyclase. Nitric oxide : biology and chemistry / official journal of the Nitric Oxide Society 2011, 25(3):265-274. | ||
+ | |||
+ | 3. Marinko M, Novakovic A, Nenezic D, Stojanovic I, Milojevic P, Jovic M, Ugresic N, Kanjuh V, Yang Q, He GW: Nicorandil directly and cyclic GMP-dependently opens K channels in human bypass grafts. Journal of pharmacological sciences 2015. |
Revision as of 08:11, 26 August 2015
Human guanylate cyclase1,soluble, beta 3 unit
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21INCOMPATIBLE WITH RFC[21]Illegal BglII site found at 579
Illegal BamHI site found at 800 - 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]
Design Notes
This part do not contains promoter so that users can add their own promotor vary from different purposes.
Source
We get the informations from this link: http://www.ncbi.nlm.nih.gov/gene/2983
References
1. Gheorghiade M, Marti CN, Sabbah HN, Roessig L, Greene SJ, Bohm M, Burnett JC, Campia U, Cleland JG, Collins SP et al: Soluble guanylate cyclase: a potential therapeutic target for heart failure. Heart failure reviews 2013, 18(2):123-134.
2. Sharina IG, Cote GJ, Martin E, Doursout MF, Murad F: RNA splicing in regulation of nitric oxide receptor soluble guanylyl cyclase. Nitric oxide : biology and chemistry / official journal of the Nitric Oxide Society 2011, 25(3):265-274.
3. Marinko M, Novakovic A, Nenezic D, Stojanovic I, Milojevic P, Jovic M, Ugresic N, Kanjuh V, Yang Q, He GW: Nicorandil directly and cyclic GMP-dependently opens K channels in human bypass grafts. Journal of pharmacological sciences 2015.